JOINT  WORKSHOP  SERIES

Screenshot (23).png

Workshop 1: Neurodegenerative Disease & Mitochondrial Function assessment

September 24, 2021

9:30 -11:30am EST/2:30- 4:30pm UK
(full agenda and speaker details below)

 

Workshop 2: Neuropsychiatry & Mitochondrial Function assessment

October 29, 2021

9:30 -11:30am EST/2:30- 4:30pm UK

 

UK Clinical Training Workshop: A patient perspective - how to diagnose mitochondrial dysfunction in the brain

November 26, 2021

8:30 -9:30am & 11:00 - 12:00-pm EST 1:30- 2:30pm & 4:00 - 5:00 pm UK

Registration CLOSED

M I T O C H O N D R I A L   &   B R A I N   I N A G U R A L   W O R K S H O P

 Workshop 2: Neuropsychiatry & Mitochondrial Function assessment

October 29, 2021

9:30 -11:30am EST/2:30- 4:30pm UK

 

AGENDA

*times shown in EST

9:30am - 9:40am
9:40am - 10:00am
10:00am - 10:20am
10:20am - 10:40am
10:40am - 11:00am
11:00am - 11:30am

Welcome Remarks:

Grainne Gorman, Wellcome Centre Mitochondrial Research

 

Dr. Peter L. Carlan: Senior Scientist, Krembil Research Institute (Krembil)
Professor, Department of Medicine, Department of Physiology, Institute of
Biomaterials and Biomedical Engineering, and Institute of Medical Science, University of Toronto

 

Dr. Nichola Lax: Post doctoral researcher

Wellcome Centre for Mitochondrial Research, Newcastle University

 

Dr. Yi Shiau Ng: Clinical Senior lecturer

Wellcome Centre for Mitochondrial Research
 

Speaker TBA

 

Panel Discussion with Moderator - Dr. Robert MacFarland,

Professor of Paediatric Mitochondrial Medicine, Wellcome Centre for Mitochondrial Research

SPEAKERS

Dr. Peter L. Carlen MD, FRCPC


Dr. Carlen obtained his MD from the University of Toronto and his
internship and Internal Medicine training at McGill University, completing his Neurology training at the University of Toronto. He also did postgraduate training in cellular electrophysiology for 3 years at the Neurobiology Unit of the Hebrew University of Jerusalem, Israel. He is a Professor in Medicine (Neurology), Physiology, and the Institute of Biomaterials and Biomedical Engineering at the University of Toronto.

He was formerly the Head of Neurology at the Addiction Research Foundation. In 1989, he was appointed Director of the Playfair Neuroscience Unit and Neuroscience Research at the University Health Network for a 10 year term, where he is now a Senior Scientist and Head of the Division of Fundamental Neurobiology. He has over 300 peer-reviewed biomedical publications and 6 patents. His main research interests are mechanisms and control of neural synchrony and entrainment in epilepsy, SUDEP, hypoglycemic seizures, gap junctional communication, brain state classification, and the cerebral pathophysiology of the fetal alcohol syndrome. He is also an active neurological clinician at the University Health Network (Toronto Western Hospital) with a practice focused mainly on patients with epilepsy.

Dr. Nichola Lax

Dr. Nichola Lax is a post-doctoral researcher within the Wellcome Centre for Mitochondrial Research at Newcastle University.

 

Together with her colleagues, she has developed a unique repository of human post-mortem brain tissues with clinically and genetically well-defined mitochondrial disease within the Newcastle Brain Tissue Resource which represents the largest (>60 brain) collection internationally. She leads a research programme which aims to identify the molecular mechanisms contributing to neurodegeneration and neurological decline in patients with mitochondrial disease. A major part of this programme is dedicated to understanding why many patients develop medically refractive epilepsy. She uses a combination of post-mortem brain tissues and model systems to identify disease mechanisms and to inform development of therapeutic targets.

Dr. Yi Shiau Ng

Dr. Yi Shiau Ng has been recently appointed as a clinical senior lecturer at Wellcome Centre for Mitochondrial Research. He is an honorary consultant neurologist who subspecializes in mitochondrial medicine. His research interests focus on acute and chronic neurological manifestations of mitochondrial disease:


1)  Understanding the natural history of stroke-like episodes (clinical, radiological, EEG and neuropathological correlates);


2) Characterizing ataxia and balance impairment in adult patients with mitochondrial disease;


3) Developing clinical practice guidelines for adult patients in collaboration with colleagues within the NHS Highly Specialized Service for Rare Mitochondrial Disorders and external experts.

Screenshot (23).png